



SHAREABLE PDF

# An emerging phenotype of pulmonary arterial hypertension patients carrying *SOX17* variants

David Montani <sup>1,2,3,13</sup>, Benoit Lechartier<sup>1,2,3,13</sup>, Barbara Girerd<sup>1,2,3</sup>, Mélanie Eyries<sup>4</sup>, Maria-Rosa Ghigna<sup>3,5</sup>, Laurent Savale <sup>1,2,3</sup>, Xavier Jaïs<sup>1,2,3</sup>, Andrei Seferian<sup>1,2,3</sup>, Mitja Jevnikar<sup>1,2,3</sup>, Athénais Boucly<sup>1,2,3</sup>, Marianne Riou<sup>6</sup>, Julie Traclet<sup>7</sup>, Ari Chaouat <sup>8</sup>, Maryline Levy<sup>9</sup>, Jerome Le Pavec<sup>2,3,10</sup>, Elie Fadel<sup>2,3,11</sup>, Frédéric Perros<sup>3</sup>, Florent Soubrier <sup>4</sup>, Martine Remy-Jardin<sup>12</sup>, Olivier Sitbon <sup>1,2,3</sup>, Damien Bonnet<sup>9</sup> and Marc Humbert <sup>1,2,3</sup>

<sup>1</sup>AP-HP, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Centre, Hôpital Bicêtre, Le Kremlin-Bicêtre, France. <sup>2</sup>School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France. <sup>3</sup>INSERM UMR\_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France. <sup>4</sup>Dépt de Génétique, Hôpital Pitié-Salpêtrière, AP-HP and UMR\_S 1166 Sorbonne Université, Paris, France. <sup>5</sup>Service d’Anatomopathologie, Hôpital Marie Lannelongue, Le Plessis-Robinson, France. <sup>6</sup>Dépt de Pneumologie, Nouvel Hôpital Civil, Strasbourg, France. <sup>7</sup>Université Lyon 1, Hospices Civils de Lyon, Centre de Référence des Maladies Pulmonaires Rares, Centre de Compétences de l’Hypertension Pulmonaire, Hôpital Louis Pradel, Lyon, France. <sup>8</sup>Université de Lorraine, CHU de Nancy, Pôle des Spécialités Médicales, Dépt de Pneumologie, Vandoeuvre-lès-Nancy, France. <sup>9</sup>Service de Cardiologie Congénitale et Pédiatrique, Hôpital Necker Enfants Malades, AP-HP, Université de Paris, Paris, France. <sup>10</sup>Service de Pneumologie et Transplantation Pulmonaire, Hôpital Marie Lannelongue, Le Plessis-Robinson, France. <sup>11</sup>Service de Chirurgie Thoracique, Hôpital Marie Lannelongue, Le Plessis-Robinson, France. <sup>12</sup>CHU de Lille, Service d’Imagerie Thoracique, Hôpital Albert Calmette, Lille, France. <sup>13</sup>D. Montani and B. Lechartier contributed equally to this work.

Corresponding author: David Montani ([david.montani@aphp.fr](mailto:david.montani@aphp.fr))



Shareable abstract (@ERSpublications)

**PAH due to *SOX17* variants is a severe phenotype associated with CHD, haemoptysis and radiological anomalies. Histopathology shows severe pulmonary arterial remodelling and malformations affecting pulmonary vessels and systemic arteries.** <https://bit.ly/3yWSYUP>

**Cite this article as:** Montani D, Lechartier B, Girerd B, *et al.* An emerging phenotype of pulmonary arterial hypertension patients carrying *SOX17* variants. *Eur Respir J* 2022; 60: 2200656 [DOI: 10.1183/13993003.00656-2022].

This single-page version can be shared freely online.

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

This article has an editorial commentary: <https://doi.org/10.1183/13993003.01438-2022>

Received: 28 March 2022  
Accepted: 17 May 2022



## Abstract

**Background** The phenotype of pulmonary arterial hypertension (PAH) patients carrying *SOX17* pathogenic variants remains mostly unknown.

**Methods** We report the genetic analysis findings, characteristics and outcomes of patients with heritable PAH carrying *SOX17* variants from the French Pulmonary Hypertension Network.

**Results** 20 patients and eight unaffected relatives were identified. The median (range) age at diagnosis was 17 (2–53) years, with a female:male ratio of 1.5. At diagnosis, most of the patients (74%) were in New York Heart Association Functional Class III or IV with severe haemodynamic compromise, including a median pulmonary vascular resistance of 14.0 (4.2–31.5) WU. An associated congenital heart disease (CHD) was found in seven PAH patients (35%). Patients with CHD-associated PAH were significantly younger at diagnosis than PAH patients without CHD. Four patients (20%) suffered from recurrent haemoptysis requiring repeated arterial embolisations. 13 out of 16 patients (81%) for whom imaging was available displayed chest computed tomography abnormalities, including dilated, tortuous pulmonary vessels, ground-glass opacities as well as anomalies of the bronchial and nonbronchial arteries. After a median (range) follow-up of 47 (1–591) months, 10 patients underwent lung transplantation and one patient benefited from a heart–lung transplantation due to associated CHD. Histopathological analysis of lung explants showed a congested lung architecture with severe pulmonary arterial remodelling, subpleural vessel dilation and numerous haemorrhagic foci.

**Conclusions** PAH due to *SOX17* pathogenic variants is a severe phenotype, frequently associated with CHD, haemoptysis and radiological abnormalities. Pathological assessment reveals severe pulmonary arterial remodelling and malformations affecting pulmonary vessels and thoracic systemic arteries.